Drug Trial Radar · NCT07361003
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jan 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
464
Planned (sponsor's estimate)
Start
Nov 12, 2025
Primary completion
Jan 2028
Study completion Jul 2028
Sponsor
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Simcere Biologics Co., Ltd
- First posted
- Jan 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of Phase Ib Study is to evaluate the safety of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. The primary goal of Phase III Study is to evaluate the efficacy of Suvemcitug in combination with trifluridine/tipiracil tablets in colorectal cancer participants. Researchers will compare Suvemcitug + trifluridine/tipiracil tablets with placebo (a look-alike substance that contains no drug)+ trifluridine/tipiracil tablets to see if Suvemcitug + trifluridine/tipiracil tablets works better in treating refractory metastatic colorectal cancer.
Conditions
- Refractory Metastatic Colorectal Cancer
Interventions
Suvemcitug injection, trifluridine/tipiracil tabletsDrug
Suvemcitug injection at 1.5mg/kg, Trifluridine/tipiracil tablets at 35 mg/m²
Suvemcitug placebo injection, trifluridine/tipiracil tabletsDrug
Suvemcitug placebo injection, Trifluridine/tipiracil tablets at 35 mg/m².
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Phase Ib: Adverse EventsTime frame: From signing informed consent form until 28 days after the last dose of study treatment, up to about 18 months
- Phase Ib: ToleranceTime frame: From signing informed consent until 28 days after the last dose of study treatment, for up to 18 months
- Phase III: overall survival (OS)Time frame: For about 18 months from the randomization of the last participant
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Harbin Medical University University Cancer Hospital
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.